RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer

RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer

Abstract Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic cancer subtype, which is generally untreatable once it metastasizes. We hypothesized that interfering with the Receptor for Advanced Glycation End-products (RAGE) signaling with the small molecule RAGE inhibitors (TT...

Full description

Bibliographic Details
Main Authors: Melinda Magna, Gyong Ha Hwang, Alec McIntosh, Katherine Drews-Elger, Masaru Takabatake, Adam Ikeda, Barbara J. Mera, Taekyoung Kwak, Philip Miller, Marc E. Lippman, Barry I. Hudson
Format: Article
Language:English
Published: Nature Portfolio 2023-07-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00564-9

Internet

https://doi.org/10.1038/s41523-023-00564-9

Similar Items